GLP-1 Formulations: Auto-Injectors vs Compounded Vials

Why formulation matters

You may already know which medication you want to ask about. What is less obvious is how it will arrive and what you will do with it each week. A brand-name single-dose pen, a brand-name vial, a daily tablet, and a compounded multi-dose vial all involve different steps, and their costs differ too.

Neither format is right for everyone. They ask different things of you, and they have different regulatory status: brand-name products are FDA-approved, and compounded products are not. Knowing what you would actually be using helps you judge whether a GLP-1 program fits your life.

Branded auto-injectors: FDA-approved pens

Brand-name GLP-1 injections are made by their manufacturers under FDA-approved applications. Most come as prefilled pens that deliver a dose measured in milligrams, so you do not calculate or convert anything. Some pens hold one dose; others hold four weekly doses. Some brand-name products also come as prefilled syringes or vials. The details below come from each product’s current FDA prescribing information.

Brand-name semaglutide options

Semaglutide for type 2 diabetes (Ozempic injection):

• Multi-dose pens for one person’s use: 2 mg/3 mL (delivers 0.25 mg or 0.5 mg doses), 4 mg/3 mL (1 mg doses), and 8 mg/3 mL (2 mg doses), plus single-dose prefilled syringes of 0.25 mg, 0.5 mg, or 1 mg per 0.5 mL^[1]
• Label dosing: 0.25 mg once weekly for 4 weeks, then 0.5 mg. If more blood sugar control is needed, 1 mg after at least 4 weeks on 0.5 mg, then 2 mg after at least 4 weeks on 1 mg. The maximum is 2 mg weekly^[1]
• Approved to improve blood sugar control in adults with type 2 diabetes, and to reduce certain cardiovascular and kidney risks in adults with type 2 diabetes who have specific heart or kidney conditions^[1]

Semaglutide for weight management (Wegovy injection):

• Single-dose pens of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg (Wegovy HD); single-dose syringes from 0.25 mg to 2.4 mg; and a four-dose pen (Wegovy FlexTouch) that delivers 2.4 mg doses^[2]
• Each single-dose pen delivers one fixed dose, so you do not set the dose yourself
• Label escalation: 0.25 mg weekly for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, and 1.7 mg for weeks 13 to 16. For weight reduction in adults, the maintenance dose from week 17 is 2.4 mg (recommended) or 1.7 mg. If 2.4 mg is tolerated for at least 4 weeks and more weight reduction is clinically indicated, the label allows an increase to a maximum of 7.2 mg weekly^[2]
• FDA-approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, adults with overweight and at least one weight-related condition, and children 12 and older with obesity. Also approved to reduce the risk of major cardiovascular events in certain adults and to treat a form of liver disease (MASH) with moderate to advanced fibrosis^[2]

Oral semaglutide tablets:

• Rybelsus tablets (3 mg, 7 mg, 14 mg) and Ozempic tablets (1.5 mg, 4 mg, 9 mg) are approved for adults with type 2 diabetes. The label says the two are not substitutable on a mg-to-mg basis^[3]
• Wegovy tablets (1.5 mg, 4 mg, 9 mg, 25 mg) are approved for weight reduction and cardiovascular risk reduction in adults. Label dosing starts at 1.5 mg once daily and steps up every 30 days to a 25 mg daily maintenance dose^[2]
• All are taken once daily on an empty stomach in the morning with up to 4 ounces of plain water, swallowed whole. Wait at least 30 minutes before eating, drinking, or taking other oral medicines^[2][3]
• The tablets contain an absorption enhancer, salcaprozate sodium (SNAC). Semaglutide from the tablet is absorbed mainly in the stomach^[3]

Brand-name tirzepatide options

Tirzepatide for type 2 diabetes (Mounjaro):

• Single-dose pens or single-dose vials of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL^[4]
• Multi-dose vials or KwikPens for one person’s use, each holding four weekly doses of 2.5 mg to 15 mg (0.6 mL per dose)^[4]
• Label dosing: 2.5 mg once weekly for 4 weeks, then 5 mg. If more blood sugar control is needed, increase in 2.5 mg steps after at least 4 weeks on the current dose. The maximum is 15 mg weekly for adults (10 mg for children 10 and older)^[4]
• Approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes^[4]

Tirzepatide for weight management (Zepbound):

• The same presentations and dose strengths as Mounjaro: single-dose pens and vials, plus four-dose multi-dose vials and KwikPens^[5]
• Label dosing: 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks. Maintenance is 5 mg, 10 mg, or 15 mg weekly for weight reduction, or 10 mg or 15 mg for obstructive sleep apnea. The maximum is 15 mg weekly^[5]
• FDA-approved, with a reduced-calorie diet and increased physical activity, for adults with obesity or adults with overweight and at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity^[5]

Features of all branded auto-injectors

Doses in milligrams, with standard strengths: Every brand-name presentation is labeled in milligrams with a set strength. Your prescriber names the dose (“0.5 mg” or “5 mg”), and the pen or syringe is made to deliver it^[6]. With a brand-name tirzepatide vial, you draw the labeled volume (0.5 mL from a single-dose vial, 0.6 mL per dose from a multi-dose vial) using a syringe that can measure it^[5].

Single-dose or multi-dose: Single-dose pens and syringes are used once and thrown away. Multi-dose pens (the Ozempic pen, Wegovy FlexTouch, and the KwikPen) hold several weekly doses, and you attach a new needle each time. The labels say never to share a pen with another person, even if the needle is changed^[1][2][5]. Dispose of needles and used pens as your product instructions and local rules direct.

Storage differs by product: Unused pens go in the refrigerator (36 to 46 degrees Fahrenheit), but the limits outside the refrigerator differ. A Wegovy single-dose pen or syringe can be kept at 46 to 86 degrees for up to 28 days if needed. A Zepbound single-dose pen or vial can be kept unrefrigerated, up to 86 degrees, for a total of 21 days. An Ozempic pen can be stored for 56 days after first use, at 59 to 86 degrees or in the refrigerator^[1][2][5]. Check the instructions for your exact product.

Made by the manufacturer, not a compounder: Brand-name products are dispensed by licensed pharmacies with a prescription for that specific product. Compounding pharmacies do not make them.

Compounded injectable vials

Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies or FDA-registered outsourcing facilities^[7]. They are not made by the brand-name manufacturers, and they are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed^[8].

The key practical difference: there is no standard compounded product. The FDA has noted that compounders offer semaglutide in different containers, including multiple-dose vials and prefilled syringes, that concentrations vary by compounder, and that a single compounder may offer several concentrations. Instructions may tell you to inject a number of “units”, and the amount of drug in a unit depends on the concentration^[6].

Semaglutide compounded vials

Concentration: Set by the pharmacy and printed on the vial label. It is not standardized, so the same number of units drawn from two different vials can contain very different amounts of semaglutide^[6].

Dose: Set by your prescriber. Compounded products have no FDA-approved dosing schedule, and a compounded dose is not equivalent to a brand-name dose. The FDA has received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed at doses beyond the FDA-approved label, taken more often, or increased faster^[8].

Administration: Usually injected under the skin once weekly, drawn from the vial with a syringe. Use the syringe the pharmacy or prescriber provides for your dose, and a new sterile needle and syringe every time^[8].

Measuring: Ask your prescriber or pharmacy for the dose in milligrams, the concentration, and the exact volume or syringe marking to draw, and ask them to show you how. FDA reports describe patients drawing 5 to 20 times the intended dose, including patients told to inject 5 units who injected 50, and providers miscalculating doses when converting milligrams to units^[6].

Tirzepatide compounded vials

Concentration and dose: The same points apply. Compounded tirzepatide has no standard concentration, and the prescriber sets the dose. The FDA has received adverse event reports that may be related to compounded tirzepatide prescribed at doses beyond the FDA-approved label^[8].

Administration: Usually injected under the skin once weekly, drawn from the vial with a syringe. Your prescriber or pharmacy should give you the exact volume to draw from your vial and a syringe suited to that volume.

Not the same as a brand-name tirzepatide vial: Zepbound and Mounjaro vials hold a labeled milligram dose in a fixed volume^[4][5]. A compounded vial’s concentration and volume are whatever the pharmacy prepared, so brand-name instructions do not carry over.

Storage for compounded vials

Refrigeration: The FDA says injectable GLP-1 drugs require refrigeration, and it recommends not using any injectable GLP-1 drug that arrives warm or without enough cooling^[8]. Follow the storage instructions on your pharmacy’s label.

The 28-day limit: The FDA generally recommends using multiple-dose vials of sterile medication within 28 days after first use because the contamination risk rises after that. It recommends discarding the vial 28 days after first use, even if medication remains and even if the compounder’s instructions say it can be used longer^[8].

Expiration: Your pharmacy labels the vial with a date. Stop using the vial at that date or 28 days after first use, whichever comes first.

Oral compounded semaglutide

Some pharmacies prepare compounded semaglutide to be taken by mouth. A 2025 search of compounding websites found single-ingredient products sold as sublingual (under the tongue) preparations or orally disintegrating tablets^[9]. These products are not FDA-approved and are not the same as Rybelsus, Ozempic tablets, or Wegovy tablets.

Absorption: The FDA-approved tablets are co-formulated with SNAC, and even so, only about 0.4% to 2% of a Rybelsus or Ozempic tablet dose reaches the bloodstream^[3]. How much semaglutide a compounded oral product delivers depends on its formulation, which the FDA has not reviewed.

Dosing: There is no standard. The pharmacy sets the strength and form, and the prescriber sets the dose and schedule. Brand-name tablet doses differ by product and are not interchangeable even with each other^[3], so they do not transfer to compounded products.

Evidence: The clinical trials behind the approved tablets studied those products. Compounded oral semaglutide has not been through FDA review for safety, effectiveness, or quality, and the authors of that review found the evidence for these formulations lacking^[9]. A licensed provider can tell you whether it is appropriate for your situation.

Unit conversion reference tables

Earlier versions of this page included milligram-to-unit conversion tables for compounded vials. We removed them, for three reasons:

• Compounded concentrations are not standardized, so any table can be wrong for your vial^[6].
• The FDA has linked dosing errors, some requiring hospitalization, to confusion between milligrams, milliliters, and “units”, and to providers miscalculating unit conversions^[6][8].
• Brand-name doses are set in milligrams for specific products. Converting a brand-name schedule into units for a compounded vial implies the two are equivalent, and they are not.

What to do instead: get your dose in writing from your prescriber, in milligrams, along with the concentration on your vial and the exact volume or syringe marking to draw. If your vial label, your instructions, and your syringe do not line up, call the pharmacy before you inject.

Pen vs vial: the practical experience

The format affects your weekly routine.

Branded auto-injector experience

With a single-dose pen, you remove the cap, place the pen on your skin, and press the button, and the pen delivers its preset dose. Multi-dose pens add a step: you attach a new needle and, on some pens, select the dose. There is no math and no drawing from a vial. If you are prescribed a brand-name vial instead, you draw a labeled volume into a syringe. Follow the Instructions for Use for your exact product, and ask for training if the presentation is new to you^[5].

The trade-off is usually cost. Brand-name products generally cost more out of pocket than compounded ones, although insurance coverage and manufacturer self-pay programs can change what you pay. Prices vary by program, product, and dose. We plan to publish current market prices with sources and capture dates; until then, compare the total cost of each option you are quoted.

Compounded vial experience

You receive a multi-dose vial and syringes. Each week, the general routine is:

1. Check the vial label (medication, concentration, and date) against your written dose instructions
2. Use a new sterile needle and syringe
3. Draw the exact volume your prescriber or pharmacy specified, using the technique they showed you
4. Check the amount in the syringe against your instructions before injecting
5. Inject under the skin as instructed, usually in the abdomen, thigh, or upper arm
6. Put the used needle and syringe in a sharps container

The vial goes back in the refrigerator. Discard it 28 days after first use, even if medication remains^[8].

Drawing from a vial takes more steps and more care than a pen. The FDA noted that many of the patients in its dosing-error reports had no experience with self-injection^[6]. If you have never drawn a dose from a vial, ask the prescriber or pharmacy for a demonstration before your first dose.

The trade-off is effort for cost. Compounded medication often costs less, but prices vary by program and dose, and some fees bundle visits, labs, and shipping while others do not.

What this means for your decision

If you are comparing GLP-1 programs, the format affects what you pay, what you do each week, and the product’s regulatory status.

Brand-name pens, syringes, vials, and tablets are FDA-approved and come in standard milligram doses with no conversion needed. Out-of-pocket cost is usually higher unless insurance or a manufacturer program covers part of it.

Compounded vials are not FDA-approved, have no standard concentration, and require careful measuring. They often cost less.

The risks on the labels apply to the medication, not the format. The labels for brand-name semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodents. These medications should not be used by people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, or people with a serious allergy to the drug. The most common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Label warnings also cover pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, and serious allergic reactions^{[1][2][3][4][5]}. Compounded products have not been evaluated by the FDA, so label information describes the brand-name products.

Before you choose, ask any program:

• Which exact product it prescribes: a brand-name product (and which presentation) or a compounded one
• For compounded products: which pharmacy prepares it, the concentration, and whether the pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility
• How the dose will be written (milligrams, plus the volume or syringe marking) and which syringes come with it
• Who you can contact with dosing questions after the medication arrives
• The total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms

Transformation Health does not accept payment from providers. How we make money.

Citations

[1] U.S. Food and Drug Administration. OZEMPIC (semaglutide) injection, prescribing information, Boxed Warning and sections 1, 2.2, 3, 4, 5, 6, and 16. Revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637Orig1s039lbl.pdf (Supports: pen and syringe strengths, dose escalation and maximum dose, indications, never share a pen, storage after first use, common side effects.)

[2] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information, Boxed Warning and sections 1, 2, 3, 4, 5, 6, and 16. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Supports: pen, syringe, FlexTouch, and tablet strengths; injection and tablet dose escalation; 2.4 mg recommended maintenance and 7.2 mg maximum; indications; tablet administration; storage; common side effects.)

[3] U.S. Food and Drug Administration. RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information, Boxed Warning and sections 1, 2, 3, 4, 5, 6, and 12.3. Revised 1/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf (Supports: tablet strengths, not substitutable mg-to-mg, administration, SNAC, absorption in the stomach, estimated absolute bioavailability, common side effects.)

[4] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information, Boxed Warning and sections 1, 2, 3, 4, 5, and 6. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf (Supports: presentations and strengths, dose escalation, adult and pediatric maximum doses, indication, common side effects.)

[5] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information, Boxed Warning and sections 1, 2, 3, 4, 5, 6, and 16. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Supports: presentations and strengths, vial syringe instructions, presentation training, dose escalation and maintenance doses, indications, never share a KwikPen, storage, common side effects.)

[6] U.S. Food and Drug Administration. “FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.” Content current as of 07/26/2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded (Accessed 2026-10-16. Supports: varying compounded containers and concentrations, instructions in units, 5 to 20 times overdoses, 5 vs 50 units example, provider conversion errors, inexperience with self-injection, approved injectable semaglutide dosed in milligrams with standard concentrations.)

[7] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16.)

[8] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: FDA does not review compounded drugs; doses beyond the approved label; 28-day multiple-dose vial recommendation; new needle and syringe each dose; refrigeration and warm shipments.)

[9] Belcourt J, Sapowadia A, White CM. “Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.” Ann Pharmacother. 2026;60(9):902-906. https://pubmed.ncbi.nlm.nih.gov/41689811/ (Supports: 2025 search of compounding sites; single-ingredient products in sublingual or orally disintegrating forms; authors cite a lack of evidence for safety and efficacy.)